312 related articles for article (PubMed ID: 31900363)
1. Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA.
Zhang P; Park HJ; Zhang J; Junn E; Andrews RJ; Velagapudi SP; Abegg D; Vishnu K; Costales MG; Childs-Disney JL; Adibekian A; Moss WN; Mouradian MM; Disney MD
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1457-1467. PubMed ID: 31900363
[TBL] [Abstract][Full Text] [Related]
2. Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera.
Tong Y; Zhang P; Yang X; Liu X; Zhang J; Grudniewska M; Jung I; Abegg D; Liu J; Childs-Disney JL; Gibaut QMR; Haniff HS; Adibekian A; Mouradian MM; Disney MD
Proc Natl Acad Sci U S A; 2024 Jan; 121(2):e2306682120. PubMed ID: 38181056
[TBL] [Abstract][Full Text] [Related]
3. The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.
Rogers JT; Mikkilineni S; Cantuti-Castelvetri I; Smith DH; Huang X; Bandyopadhyay S; Cahill CM; Maccecchini ML; Lahiri DK; Greig NH
J Neural Transm (Vienna); 2011 Mar; 118(3):493-507. PubMed ID: 21221670
[TBL] [Abstract][Full Text] [Related]
4. Constitutive translation of human α-synuclein is mediated by the 5'-untranslated region.
Koukouraki P; Doxakis E
Open Biol; 2016 Apr; 6(4):160022. PubMed ID: 27248657
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies.
Tagliafierro L; Glenn OC; Zamora ME; Beach TG; Woltjer RL; Lutz MW; Chiba-Falek O
Alzheimers Dement; 2017 Nov; 13(11):1237-1250. PubMed ID: 28431219
[TBL] [Abstract][Full Text] [Related]
6. Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease.
Bandyopadhyay S; Cahill C; Balleidier A; Huang C; Lahiri DK; Huang X; Rogers JT
PLoS One; 2013; 8(7):e65978. PubMed ID: 23935819
[TBL] [Abstract][Full Text] [Related]
7. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
Tóth G; Gardai SJ; Zago W; Bertoncini CW; Cremades N; Roy SL; Tambe MA; Rochet JC; Galvagnion C; Skibinski G; Finkbeiner S; Bova M; Regnstrom K; Chiou SS; Johnston J; Callaway K; Anderson JP; Jobling MF; Buell AK; Yednock TA; Knowles TP; Vendruscolo M; Christodoulou J; Dobson CM; Schenk D; McConlogue L
PLoS One; 2014; 9(2):e87133. PubMed ID: 24551051
[TBL] [Abstract][Full Text] [Related]
8. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease.
Uehara T; Choong CJ; Nakamori M; Hayakawa H; Nishiyama K; Kasahara Y; Baba K; Nagata T; Yokota T; Tsuda H; Obika S; Mochizuki H
Sci Rep; 2019 May; 9(1):7567. PubMed ID: 31110191
[TBL] [Abstract][Full Text] [Related]
9. Discovering the 3' UTR-mediated regulation of alpha-synuclein.
Marchese D; Botta-Orfila T; Cirillo D; Rodriguez JA; Livi CM; Fernández-Santiago R; Ezquerra M; Martí MJ; Bechara E; Tartaglia GG;
Nucleic Acids Res; 2017 Dec; 45(22):12888-12903. PubMed ID: 29149290
[TBL] [Abstract][Full Text] [Related]
10. Variant in the 3' region of SNCA associated with Parkinson's disease and serum α-synuclein levels.
Hu Y; Tang B; Guo J; Wu X; Sun Q; Shi C; Hu L; Wang C; Wang L; Tan L; Shen L; Yan X; Zhang H
J Neurol; 2012 Mar; 259(3):497-504. PubMed ID: 21853288
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
12. Alpha-Synuclein RNA Expression is Increased in Major Depression.
Rotter A; Lenz B; Pitsch R; Richter-Schmidinger T; Kornhuber J; Rhein C
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027150
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Parkinson's disease-associated genes by Pumilio proteins and microRNAs in SH-SY5Y neuronal cells.
Snoderly-Foster LJ; Olivas WM
PLoS One; 2022; 17(9):e0275235. PubMed ID: 36174040
[TBL] [Abstract][Full Text] [Related]
14. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.
McLean JR; Hallett PJ; Cooper O; Stanley M; Isacson O
Mol Cell Neurosci; 2012 Feb; 49(2):230-9. PubMed ID: 22155155
[TBL] [Abstract][Full Text] [Related]
15. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.
Chiba-Falek O; Lopez GJ; Nussbaum RL
Mov Disord; 2006 Oct; 21(10):1703-8. PubMed ID: 16795004
[TBL] [Abstract][Full Text] [Related]
16. CCAAT/enhancer binding protein δ is a transcriptional repressor of α-synuclein.
Valente T; Dentesano G; Ezquerra M; Fernandez-Santiago R; Martinez-Martin J; Gallastegui E; Domuro C; Compta Y; Martí MJ; Bachs O; Márquez-Kisinousky L; Straccia M; Solà C; Saura J
Cell Death Differ; 2020 Feb; 27(2):509-524. PubMed ID: 31209363
[TBL] [Abstract][Full Text] [Related]
17. Dihydroquinazolines enhance 20S proteasome activity and induce degradation of α-synuclein, an intrinsically disordered protein associated with neurodegeneration.
Fiolek TJ; Magyar CL; Wall TJ; Davies SB; Campbell MV; Savich CJ; Tepe JJ; Mosey RA
Bioorg Med Chem Lett; 2021 Mar; 36():127821. PubMed ID: 33513387
[TBL] [Abstract][Full Text] [Related]
18. Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression.
Schmitt I; Wüllner U; van Rooyen JP; Khazneh H; Becker J; Volk A; Kubisch C; Becker T; Kostic VS; Klein C; Ramirez A
Eur J Hum Genet; 2012 Dec; 20(12):1265-9. PubMed ID: 22617348
[TBL] [Abstract][Full Text] [Related]
19. A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease.
Sotiriou S; Gibney G; Baxevanis AD; Nussbaum RL
Neurosci Lett; 2009 Sep; 461(2):196-201. PubMed ID: 19540308
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 2 modulates α-synuclein protein levels by regulating its mRNA production.
Kofoed RH; Zheng J; Ferreira N; Lykke-Andersen S; Salvi M; Betzer C; Reimer L; Jensen TH; Fog K; Jensen PH
Neurobiol Dis; 2017 Oct; 106():49-62. PubMed ID: 28648742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
